131 related articles for article (PubMed ID: 26328528)
1. Activated-platelet targeting of CD39 as a potential way forward. The quest for efficient antithrombotic therapy without associated bleeding complications.
Hohmann JD; Peter K
Hamostaseologie; 2016; 36(1):17-25. PubMed ID: 26328528
[TBL] [Abstract][Full Text] [Related]
2. Delayed targeting of CD39 to activated platelet GPIIb/IIIa via a single-chain antibody: breaking the link between antithrombotic potency and bleeding?
Hohmann JD; Wang X; Krajewski S; Selan C; Haller CA; Straub A; Chaikof EL; Nandurkar HH; Hagemeyer CE; Peter K
Blood; 2013 Apr; 121(16):3067-75. PubMed ID: 23380744
[TBL] [Abstract][Full Text] [Related]
3. Metabolic control of excessive extracellular nucleotide accumulation by CD39/ecto-nucleotidase-1: implications for ischemic vascular diseases.
Marcus AJ; Broekman MJ; Drosopoulos JH; Islam N; Pinsky DJ; Sesti C; Levi R
J Pharmacol Exp Ther; 2003 Apr; 305(1):9-16. PubMed ID: 12649347
[TBL] [Abstract][Full Text] [Related]
4. Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation.
Stoll P; Bassler N; Hagemeyer CE; Eisenhardt SU; Chen YC; Schmidt R; Schwarz M; Ahrens I; Katagiri Y; Pannen B; Bode C; Peter K
Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1206-12. PubMed ID: 17322097
[TBL] [Abstract][Full Text] [Related]
5. Current and future antiplatelet therapies: emphasis on preserving haemostasis.
McFadyen JD; Schaff M; Peter K
Nat Rev Cardiol; 2018 Mar; 15(3):181-191. PubMed ID: 29297508
[TBL] [Abstract][Full Text] [Related]
6. BF061, a novel antiplatelet and antithrombotic agent targeting P2Y₁₂ receptor and phosphodiesterase.
Hu L; Fan Z; Du H; Ni R; Zhang S; Yin K; Ye J; Zhang Y; Wei X; Zhang X; Gross PL; Kunapuli SP; Ding Z
Thromb Haemost; 2011 Dec; 106(6):1203-14. PubMed ID: 21946947
[TBL] [Abstract][Full Text] [Related]
7. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39.
Marcus AJ; Broekman MJ; Drosopoulos JH; Islam N; Alyonycheva TN; Safier LB; Hajjar KA; Posnett DN; Schoenborn MA; Schooley KA; Gayle RB; Maliszewski CR
J Clin Invest; 1997 Mar; 99(6):1351-60. PubMed ID: 9077545
[TBL] [Abstract][Full Text] [Related]
8. Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection.
Marcus AJ; Broekman MJ; Drosopoulos JH; Olson KE; Islam N; Pinsky DJ; Levi R
Semin Thromb Hemost; 2005 Apr; 31(2):234-46. PubMed ID: 15852226
[TBL] [Abstract][Full Text] [Related]
9. Reconstitution of CD39 in liposomes amplifies nucleoside triphosphate diphosphohydrolase activity and restores thromboregulatory properties.
Haller CA; Cui W; Wen J; Robson SC; Chaikof EL
J Vasc Surg; 2006 Apr; 43(4):816-23. PubMed ID: 16616242
[TBL] [Abstract][Full Text] [Related]
10. Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets.
Schwarz M; Meade G; Stoll P; Ylanne J; Bassler N; Chen YC; Hagemeyer CE; Ahrens I; Moran N; Kenny D; Fitzgerald D; Bode C; Peter K
Circ Res; 2006 Jul; 99(1):25-33. PubMed ID: 16778135
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of CD39/ecto-nucleoside triphosphate diphosphohydrolase-1 in murine intestinal ischemia-reperfusion injury.
Guckelberger O; Sun XF; Sévigny J; Imai M; Kaczmarek E; Enjyoji K; Kruskal JB; Robson SC
Thromb Haemost; 2004 Mar; 91(3):576-86. PubMed ID: 14983235
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of platelet recruitment by endothelial cell CD39/ecto-ADPase: significance for occlusive vascular diseases.
Marcus AJ; Broekman MJ; Drosopoulos JH; Pinsky DJ; Islam N; Maliszewsk CR
Ital Heart J; 2001 Nov; 2(11):824-30. PubMed ID: 11770867
[TBL] [Abstract][Full Text] [Related]
13. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys.
Kaku S; Kawasaki T; Hisamichi N; Sakai Y; Taniuchi Y; Inagaki O; Yano S; Suzuki K; Terazaki C; Masuho Y; Satoh N; Takenaka T; Yanagi K; Ohshima N
Thromb Haemost; 1996 Apr; 75(4):679-84. PubMed ID: 8743199
[TBL] [Abstract][Full Text] [Related]
14. Platelet-targeted thromboprophylaxis with a human serum albumin fusion drug: Preventing thrombosis and reducing cardiac ischemia/reperfusion injurywithout bleeding complications.
Song Y; Bienvenu LA; Bongcaron V; Prijaya SA; Maluenda AC; Walsh APG; McFayden JD; Pietersz GA; Peter K; Wang X
Theranostics; 2024; 14(8):3267-3281. PubMed ID: 38855181
[No Abstract] [Full Text] [Related]
15. Ginkgo biloba extract enhances antiplatelet and antithrombotic effects of cilostazol without prolongation of bleeding time.
Ryu KH; Han HY; Lee SY; Jeon SD; Im GJ; Lee BY; Kim K; Lim KM; Chung JH
Thromb Res; 2009 Jul; 124(3):328-34. PubMed ID: 19349067
[TBL] [Abstract][Full Text] [Related]
16. New developments in anti-platelet therapies: potential use of CD39/vascular ATP diphosphohydrolase in thrombotic disorders.
Qawi I; Robson SC
Curr Drug Targets; 2000 Nov; 1(3):285-96. PubMed ID: 11465076
[TBL] [Abstract][Full Text] [Related]
17. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding.
Goto S
Atheroscler Suppl; 2005 Dec; 6(4):3-11. PubMed ID: 16275169
[TBL] [Abstract][Full Text] [Related]
18. [Bridging: Perioperative management of chronic anticoagulation or antiplatelet therapy].
Nowak-Göttl U; Langer F; Limperger V; Mesters R; Trappe RU
Dtsch Med Wochenschr; 2014 Jun; 139(24):1301-6. PubMed ID: 24892468
[TBL] [Abstract][Full Text] [Related]
19. Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation.
Dwyer KM; Robson SC; Nandurkar HH; Campbell DJ; Gock H; Murray-Segal LJ; Fisicaro N; Mysore TB; Kaczmarek E; Cowan PJ; d'Apice AJ
J Clin Invest; 2004 May; 113(10):1440-6. PubMed ID: 15146241
[TBL] [Abstract][Full Text] [Related]
20. GPIIb/IIIa inhibitors: from bench to bedside and back to bench again.
Armstrong PC; Peter K
Thromb Haemost; 2012 May; 107(5):808-14. PubMed ID: 22370973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
